🔗 Share this article

While the US continues making historic revisions to its vaccine recommendations, a particular individual appears in a surprising turn: Høeg, an American of Danish descent sports physician and public health researcher who rose to prominence by casting doubt on coronavirus shots during the global health crisis and has zeroed in on potential deaths following COVID-19 immunization in her brief time at the Food and Drug Administration.

Scheduled Shifts to Pediatric Immunization Program

Health officials planned to reveal major changes to the pediatric vaccination calendar recently, aligning the US with Denmark’s immunization schedule, it is understood – a major change that would put the US at odds with much of the world with little proof for improved outcomes. The announcement has been postponed until the new year.

In place of Vinay Prasad, Tracy Beth Høeg is listed to address the audience at the gathering. She was recently named acting director of the FDA’s drug evaluation center, the fifth individual to lead the center this calendar year.

A Shift at the FDA

Høeg's temporary position might represent a tighter collaboration between the pharmaceutical and biologics centers as Høeg and Dr. Prasad strengthen their influence at the agency – and it suggests a increased emphasis upon reevaluating previously authorized vaccines at the FDA.

Høeg has frequently advocated for ending specific childhood immunization guidelines in the US in order to be more similar to Denmark, a country with nationalized medicine and a population roughly the population of Wisconsin’s.

To date comments, she has persisted in emphasizing on immunizations – typically the purview of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Doubts Over Background

Høeg has no obvious experience in pharmaceutical research, oversight or administrative roles, which has been typical for previous heads of the biologics center. She has served at the FDA as a key advisor to the FDA chief and CBER since March.

“She doesn’t seem to have any of the qualifications” for leading the CDER, remarked Jonathan Howard. “She’s never run a clinical trial. She is not versed in running a major agency. She has no expertise in drug approvals.”

Past commissioners of the center would “understand laws and regulations and the research of drug development”, said Janet Woodcock. “Clearly, she doesn’t have the type of experience that former directors who ran CBER have had.”

This division has an immense workload at the agency, the former commissioner pointed out.

“Everybody just focuses on the innovative therapies, but the off-patent medication office approves numerous generic drugs. There is also a biosimilars division, over-the-counter program and more, and all of those have to be supervised,” Dr. Woodcock explained. “The thing you overlook, that is the part that I always told people is going to cause problems.”

Furthermore, a significant administrative element to the job, which oversees in excess of 5,000 employees. “It is a huge management job, if you perform it correctly,” the former official said.

Response and Controversial Initiatives

Regarding inquiries about Dr. Høeg's credentials and whether this selection indicates increased cooperation among regulatory chiefs on immunizations, a press secretary said that the “concerns rely on flawed presumptions”.

“Her resume is consistent with the functions of her role,” the official said, citing the time Høeg spent advising the FDA commissioner on “medication safety and approval science, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's controversial fast-track approval initiative, a contentious one-day medication authorization process that apparently troubled her preceding directors. “How are these medications being selected for this voucher program? Who makes the calls?” Howard said. “There’s a lot of lack of transparency going on at the regulatory body right now.”

In general, he stated, “the agency seems to be moving towards less stringent rules of most medications, aside from immunizations.”

Documented History on Immunizations

Regarding immunizations, Dr. Høeg has a more documented, if problematic, track record, Howard observe. She published a research paper using unverified crowd-sourced reports to estimate the frequency of myocarditis after Covid immunization. She consulted for the state of Florida top health official Joseph Ladapo, who reportedly have modified findings to imply Covid vaccines are riskier than they are.

Included in her “policy goals” for the current federal leadership encompassed altering rules for recently developed shots and halting “optional” vaccines, she stated after the election on a podcast. At the FDA, Dr. Høeg has reportedly suggested barring young men from receiving COVID-19 vaccinations.

“She is an all-around ideologue who commences with her beliefs and tailors the evidence to retrofit the science in a highly misleading, fraudulent fashion,” Howard argued.

Gaining Influence and a “Revenge Tour”

Dr. Høeg became part of fellow skeptics, {like|